Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
Robert L. Kormos(Abbott Northwestern Hospital), Bartley P. Griffith(University of Maryland, Baltimore), Keith L. Stein, David B. Herlan, R Duquesnoy, A. Zeevi, Christina L. Kaufman(University of Louisville), R L Hardesty, James M. Armitage(ASL Environmental Sciences (Canada))
PubMed
April 16, 1990
Cited by 20
Related Papers
REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY
|The Lancet|1984|1.3k
PFAS Exposure Pathways for Humans and Wildlife: A Synthesis of Current Knowledge and Key Gaps in Understanding
|Environmental Toxicology and Chemistry|2020|782
Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation
|Circulation|2012|655
Rates and Risk Factors for Nonadherence to the Medical Regimen After Adult Solid Organ Transplantation
|Transplantation|2007|575
Venous Bypass in Clinical Liver Transplantation
|Annals of Surgery|1984|554